Compare · ORKA vs QCLS
ORKA vs QCLS
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.13B, about 417.8x QCLS ($14.7M).
- Over the past year, ORKA is up 497.5% and QCLS is down 49.0% - ORKA leads by 546.5 points.
- ORKA has been more active in the news (10 items in the past 4 weeks vs 1 for QCLS).
- ORKA has more recent analyst coverage (11 ratings vs 0 for QCLS).
PerformanceORKA+497.50%QCLS-49.00%
2025-09-08+0.00%2026-09-08
- Company
- Oruka Therapeutics Inc.
- Q/C Technologies Inc.
- Price
- $94.47+2.03%
- $1.91+7.30%
- Market cap
- $6.13B
- $14.7M
- 1M return
- -4.33%
- -34.25%
- 1Y return
- +497.50%
- -49.00%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 1
- Recent ratings
- 11
- 0
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
Latest QCLS
- SEC Form 3 filed by new insider Fagan Charles Todd
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Director Voss Chelsea Sierra bought $5,522 worth of shares (1,753 units at $3.15) (SEC Form 4)
- Amendment: SEC Form 10-K/A filed by Q/C Technologies Inc.
- SEC Form 4 filed by White Billy Joe
- SEC Form 4 filed by Friscia Stephen